Fisetin for Anti-Inflammatory

Research suggests that fisetin possesses meaningful anti-inflammatory properties across a range of laboratory and animal models, with studies demonstrating its ability to suppress key inflammatory signaling pathways — including NF-κB, MAPK, IL-6/JAK2/STAT3, and HMGB1 — and reduce pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in contexts ranging from kidney disease and osteoarthritis to sepsis and liver cancer. The available evidence base consists primarily of cell culture experiments and animal studies, along with several narrative reviews, with no randomized controlled trials in humans identified among the reviewed literature, which substantially limits conclusions about how these findings translate to people. Some mixed signals exist within this body of work — notably, one 2011 study found that fisetin unexpectedly enhanced certain pro-inflammatory signaling cascades (ERK and JNK) and failed to reduce paw swelling in a mouse model, unlike structurally similar flavonoids, underscoring that fisetin's effects may vary depending on the specific inflammatory pathway, cell type, or disease context being examined. Overall, the preclinical evidence is generally supportive and points to fisetin as a candidate of interest for inflammation-related research, but human clinical data are needed before firm conclusions can be drawn about its efficacy or practical therapeutic role.